Journal of Applied Physiology Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Appl Physiol 107: 1431-1437, 2009. First published September 10, 2009; doi:10.1152/japplphysiol.91081.2008
8750-7587/09 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
107/5/1431    most recent
91081.2008v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Karlsson, L. L.
Right arrow Articles by Linnarsson, D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karlsson, L. L.
Right arrow Articles by Linnarsson, D.

Microgravity decreases and hypergravity increases exhaled nitric oxide

Lars L. Karlsson,1 Yannick Kerckx,2 Lars E. Gustafsson,1 Tryggve E. Hemmingsson,1 and Dag Linnarsson1

1Department of Physiology and Pharmacology, Section of Environmental Physiology, Karolinska Institutet, Stockholm, Sweden; and ; 2Biomedical Physics Laboratory, Université Libre de Bruxelles, Brussels, Belgium

Submitted 11 August 2008 ; accepted in final form 8 September 2009

Inhalation of toxic dust during planetary space missions may cause airway inflammation, which can be monitored with exhaled nitric oxide (NO). Gravity will differ from earth, and we hypothesized that gravity changes would influence exhaled NO by altering lung diffusing capacity and alveolar uptake of NO. Five subjects were studied during microgravity aboard the International Space Station, and 10 subjects were studied during hypergravity in a human centrifuge. Exhaled NO concentrations were measured during flows of 50 (all gravity conditions), 100, 200, and 500 ml/s (hypergravity). During microgravity, exhaled NO fell from a ground control value of 12.3 ± 4.7 parts/billion (mean ± SD) to 6.6 ± 4.4 parts/billion (P = 0.016). In the centrifuge experiments and at the same flow, exhaled NO values were 16.0 ± 4.3, 19.5 ± 5.1, and 18.6 ± 4.7 parts/billion at one, two, and three times normal gravity, where exhaled NO in hypergravity was significantly elevated compared with normal gravity (P ≤ 0.011 for all flows). Estimated alveolar NO was 2.3 ± 1.1 parts/billion in normal gravity and increased significantly to 3.9 ± 1.4 and 3.8 ± 0.8 parts/billion at two and three times normal gravity (P < 0.002). The findings of decreased exhaled NO in microgravity and increased exhaled and estimated alveolar NO values in hypergravity suggest that gravity-induced changes in alveolar-to-lung capillary gas transfer modify exhaled NO.

estimates of alveolar NO; analysis of exhaled NO; human centrifuge; lung diffusion; respiratory system; weightlessness



Address for reprint requests and other correspondence: L. Karlsson, Section of Environmental Physiology, Dept. of Physiology and Pharmacology, Karolinska Institutet, Berzelius v. 13, SE-171 77 Stockholm, Sweden (e-mail: lars.karlsson{at}ki.se).







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2009 by the American Physiological Society.